Application

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected LGMN in human placenta, human kidney, and human small intestine.

Anti-LGMN, clone 6A7.2 Antibody, Cat. No. MABN2185, is a highly specific mouse monoclonal antibody that targets LGMN and has been tested in Western Blotting and Immunohistochemistry (Paraffin).

General description

Legumain (UniProt: Q99538; EC:3.4.22.34, also known as Asparaginyl endopeptidase; Protease, cysteine 1) is encoded by LGMN (also known as PRSC1) gene (Gene ID 5641) in human. Legumain is a lysosomal enzyme with strict specificity of the hydrolysis of asparaginyl bonds. It is shown to be ubiquitously distributed with abundance in kidney, heart, and placenta. In the zymogen form, the uncleaved propeptide blocks access to the active site. It is activated autocatlytically by acidic pH and the active form is shown to be monomeric. Legumain plays a pivotal role in the endosomal/lysosomal degradation system and is involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation. Legumain deficiency causes the accumulation of pro-cathepsins B, H and L. Overexpression of legumain is associated with invasion and metastasis in a majority of solid tumors.

Immunogen

GST-tagged recombinant fragment corresponding to 95 amino acids from the internal region of human LGMN.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Format: Purified

Quality

Evaluated by Western Blotting in human heart tissue lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected LGMN in 10 µg of human heart tissue lysate.

Specificity

Clone 6A7.2 of detects LGMN in multiple human tissues by Western blotting and immunohistochemistry.

Target description

~ 55 kDa observed; 49.4 kDa calculated. Uncharacterized bands may be observed in some lysate(s).